Matches in DBpedia 2016-04 for { ?s ?p "CytoSorbents is a critical –care focused publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey. Cytosorbents has created a blood purification technology based on biocompatible, highly porous polymer beads that act like sponges to remove harmful substances from the blood.CytoSorb, the Company's first product to market, received its CE mark approval in 2011. The product is currently used in Europe for critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorbents is the vertically integrated ISO 13485 certified manufacturer of CytoSorb.CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma. The US Air Force is funding a $3million FDA approved randomized controlled trial in trauma and rhabdomyolysis."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Cytosorbents abstract "CytoSorbents is a critical –care focused publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey. Cytosorbents has created a blood purification technology based on biocompatible, highly porous polymer beads that act like sponges to remove harmful substances from the blood.CytoSorb, the Company's first product to market, received its CE mark approval in 2011. The product is currently used in Europe for critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorbents is the vertically integrated ISO 13485 certified manufacturer of CytoSorb.CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma. The US Air Force is funding a $3million FDA approved randomized controlled trial in trauma and rhabdomyolysis.".
- Q17182820 abstract "CytoSorbents is a critical –care focused publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey. Cytosorbents has created a blood purification technology based on biocompatible, highly porous polymer beads that act like sponges to remove harmful substances from the blood.CytoSorb, the Company's first product to market, received its CE mark approval in 2011. The product is currently used in Europe for critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorbents is the vertically integrated ISO 13485 certified manufacturer of CytoSorb.CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma. The US Air Force is funding a $3million FDA approved randomized controlled trial in trauma and rhabdomyolysis.".